What is William Blair’s Forecast for BMRN Q1 Earnings?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of BioMarin Pharmaceutical in a report issued on Thursday, February 20th. William Blair analyst S. Corwin forecasts that the biotechnology company will post earnings of $0.93 per share for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. William Blair also issued estimates for BioMarin Pharmaceutical’s Q2 2026 earnings at $0.97 EPS and Q3 2026 earnings at $0.98 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%.

Several other brokerages have also recently commented on BMRN. Royal Bank of Canada reiterated a “sector perform” rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. JPMorgan Chase & Co. decreased their price target on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 30th. StockNews.com upgraded BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday. Wolfe Research started coverage on BioMarin Pharmaceutical in a report on Friday, November 15th. They set an “outperform” rating and a $95.00 price objective for the company. Finally, Citigroup boosted their target price on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.00.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $71.17 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The firm has a market capitalization of $13.56 billion, a P/E ratio of 32.35, a PEG ratio of 0.61 and a beta of 0.28. The company’s fifty day moving average is $65.03 and its two-hundred day moving average is $70.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Oregon Public Employees Retirement Fund boosted its position in shares of BioMarin Pharmaceutical by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company’s stock worth $2,546,000 after acquiring an additional 164 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of BioMarin Pharmaceutical by 13.9% in the 4th quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 165 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of BioMarin Pharmaceutical by 0.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 21,105 shares of the biotechnology company’s stock valued at $1,483,000 after buying an additional 173 shares during the period. Advisors Asset Management Inc. increased its holdings in shares of BioMarin Pharmaceutical by 1.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company’s stock worth $805,000 after buying an additional 180 shares during the last quarter. Finally, Freedom Investment Management Inc. increased its holdings in shares of BioMarin Pharmaceutical by 3.8% during the 4th quarter. Freedom Investment Management Inc. now owns 5,022 shares of the biotechnology company’s stock worth $330,000 after buying an additional 184 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Erin Burkhart sold 1,344 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $68.38, for a total transaction of $91,902.72. Following the transaction, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.85% of the stock is owned by corporate insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.